Acumen Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.
Acumen Pharmaceuticals has raised $166M across 2 funding rounds on record, the most recent an undisclosed round of $35.8M announced in Mar 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Acumen Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Acumen Pharmaceuticals Funding Rounds
Acumen Pharmaceuticals raised $130M in an undisclosed round announced in Jul 2023.
2.7 years later, an undisclosed round of $35.8M was announced in Mar 2026.
Acumen Pharmaceuticals Founders and Leadership Team
Contact details for the Acumen Pharmaceuticals team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Acumen Pharmaceuticals Funding Compared to Other Biotechnology Startups
Acumen Pharmaceuticals' latest round of $35.8M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Acumen Pharmaceuticals in Biotechnology and Carmel
Companies Similar to Acumen Pharmaceuticals
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Acumen Pharmaceuticals Funding FAQs
What does Acumen Pharmaceuticals do?
Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.
How much funding has Acumen Pharmaceuticals raised?
Acumen Pharmaceuticals has raised $166M across 2 rounds on record. The most recent is an undisclosed round of $35.8M announced in Mar 2026.
When did Acumen Pharmaceuticals last raise funding?
Acumen Pharmaceuticals' most recent funding round on record is an undisclosed round of $35.8M, announced in Mar 2026.
Who founded Acumen Pharmaceuticals?
FundedIQ lists Daniel O'connell (Founder), William Goure (Founder) at Acumen Pharmaceuticals.
Where is Acumen Pharmaceuticals headquartered?
Acumen Pharmaceuticals is based in Carmel, Indiana, United States.
How many employees does Acumen Pharmaceuticals have?
Acumen Pharmaceuticals is in the 11-50 employee band.
How does Acumen Pharmaceuticals' funding compare to other Biotechnology startups?
Acumen Pharmaceuticals' latest round of $35.8M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Acumen Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Acumen Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.